Dr. Shruti Naik is an Assistant Professor of Biological Sciences at New York University Langone Medical Center. She studies immunity in the epithelial tissues that line our body to understand how environmental stimuli collaborate with genetic factors to influence health and drive disease at these interfaces. She discusses the work she’s presenting at the American Association of Immunologists’ annual meeting, IMMUNOLOGY2022, on trained immunity and immune-epithelial crosstalk in tissue repair.
Dr. Gwendalyn Randolph is the Emil R. Unanue Distinguished Professor in the Department of Immunology and Pathology at Washington University in St. Louis. Research in her lab integrates the study of monocytes, monocyte-derived cells, and dendritic cells with vascular and lymphatic vessel biology. She discusses the work she’s presenting at the American Association of Immunologists’ annual meeting, IMMUNOLOGY2022, on the diversity, function, and mysteries of peritoneal macrophages.
Dr. Michael Rosenblum is a Professor of Dermatology at the University of California, San Francisco. His lab seeks to to understand how immune responses are regulated in tissues and how this knowledge can be exploited for therapeutic benefit. They are currently investigating how Tregs control immune responses in tissues, as well as their “alternative” functions. He talks about early-life inflammation and type 2 helper T cells in the skin, and how Tregs can be manipulated to target autoimmune diseases and cancer.
Dr. Gary Koretzky is President of the American Association of Immunologists, Vice Provost for Academic Integration at Cornell University, Professor of Medicine at Weill Cornell Medicine, and Director of the Cornell Center for Immunology. He talks about how he began his career in immunology, using science to guide Cornell’s response to COVID-19, and what to expect at AAI’s Immunology 2022 meeting taking place May 6-10th.
Dr. Florian Krammer is a Professor of Vaccinology at Icahn School of Medicine at Mount Sinai. His lab focuses on understanding broadly-reactive immune responses against the surface glycoproteins of RNA viruses such as influenza, with the goal to develop better vaccines and novel therapeutics. He talks about his lab’s shift to COVID-19 research, strategies for vaccine development, and how we can prepare for future pandemics.